Innovations in rare blood disorders took center stage at the 2024 American Society of Hematology (ASH) Annual Meeting & ...

Sanofi’s Sarclisa shows significant Phase III results for multiple myeloma, delivering deeper and longer-lasting responses in ...

New data from three oral presentations, which demonstrated significant clinical benefit with Sarclisa-based quadruplets in newly diagnosed multiple myeloma (NDMM) patients were featured at the 66th ...

ASH: Sarclisa combinations demonstrated significant benefits in newly diagnosed multiple myeloma patientsNew analysis from the IMROZ phase 3 ...

Sanofi (SNY) says new data from three oral presentations demonstrated significant clinical benefit with Sarclisa-based quadruplets in newly ...

One of the major stories in multiple myeloma in 2024 was the comeback of belantamab mafodotin (Blenrep) after it had been ...

Also, we talk about how Sarclisa trials highlighted racial disparities in clinical trial composition, and more.

Additionally, positive clinical trials for myeloma drug, Sarclisa and a Phase 3 Multiple Sclerosis asset also boosted shares. At current levels, we view Sanofi’s vaccines business as ...

The suspected madman behind a deadly stabbing spree in Manhattan Monday has a long criminal history — and had just walked free from Rikers Island a month before the terrifying attacks, The Post ...

Sanofi’s Sarclisa received a positive recommendation from the EMA’s CHMP for treating newly diagnosed multiple myeloma patients ineligible for stem cell transplants. This recommendation ...

Paris: Sanofi has announced that the European Medicines Agency (EMA)'s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the approval of Sarclisa in ...

The European Medicines Agency (EMA)’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the approval of Sarclisa in combination with bortezomib, ...